Skip to main content

Table 3 Change in CMT at each time point following transition to aflibercept therapy

From: Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab

Time point CMTa
(Mean ± SD)
Change from Baseline
(Mean ± SD)
Change from Baseline
(%)
P-valueb 95% CI
Lower Upper
Baseline 387 ± 99      
Month 1 326 ± 90 − 64 ± 75 15  < 0.0001 85 − 43
Month 3 345 ± 88 − 42 ± 85 8 0.002 − 66 − 18
Month 6 341 ± 96 − 47 ± 69 11  < 0.0001 − 66 − 28
Month 12 342 ± 96 − 46 ± 99 9 0.001 − 73 − 18
  1. CMT central macular thickness, CI: confidence interval
  2. a μM
  3. b Based on hybrid linear mixed model, adjusted for multiple comparisons based on Sidak method
\